John Ning, MD, PhD

SVP, Oncology Clinical Development

Dr. Ning is the clinical and program lead for the Oncology program at HUYABIO, with pharmaceutical and biotech experience in clinical development and operations, translational research, medical affairs, pharmacovigilance and drug safety. With over 30 years experience, he previously served as the Chief Medical Officer at SillaJen Biotherapeutics, focusing on immuno-oncology therapeutic development, at Genentech in Oncology Product Development Clinical and Safety Sciences, and was involved with the clinical and post-approval product development of many successful drugs on the market today. John worked at Zogenix, Ferring Pharmaceuticals, Bristol-Myers Squibb, Baxter Healthcare and Roche Laboratory. Dr. Ning received his PhD in Biochemistry and Molecular Biology and an  MD from Virginia Commonwealth University School of Medicine, an MS in Pharmacology and an MS in Medical Laboratory Sciences from Northeastern University, and a BS in Chemistry from Massachusetts Institute of Technology.